Earnings Call · Q1 FY2026·2026-04-30

Q1 26EPS -21.57%·Rev n/aQ4 25EPS +46.34%·Rev n/aQ3 25EPS +21.43%·Rev n/aQ2 25EPS +7.69%·Rev n/a⚠ consensus missing

NovoCure Ltd NVCR

Adam Daney — Investor Relations

William Doyle — Executive Chairman

Frank Leonard — Chief Executive Officer

Christoph Brackmann — Chief Financial Officer

+27.5%1d on move date+26.5% vs SPY3d+41.9%5d+38.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NVCR calls or request research access.

More NVCR calls Browse calls Request research access